My own ophthalmologist raves about the ReStor lens from Alcon. It’s a technological marvel, but there has been substantial pushback from managed care regarding the premium price. As a result, its market share among all IOL’s remains stuck in the mid single digits. Regards, Dew
p.s. Do you have any further comments re #msg-24682767 (diminishing returns in drug discovery)?
Market Data 
Markets 
AI
